In Brief This Week: Abbott; PerkinElmer; Medical College of Wisconsin; Leica Biosystems; Accelrys; Five3 Genomics | GenomeWeb

NEW YORK (GenomeWeb News) – Abbott said this week that it will expand the current CE-IVD product labeling for its Vysis ALK Break Apart FISH Probe Kit, allowing the test to be marketed in the European Union as a companion diagnostic. The test is designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in advanced non-small cell lung cancer patients who may be eligible for treatment with Pfizer's Xalkori (crizotinib), an oral first-in-class ALK inhibitor.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.